おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Acer Therapeutics
About
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
- Newton,Massachusetts,United States
- 11 - 50
- http://www.acertx.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $1.50M
- Industries
- Biotechnology,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Stock Symbol
- nasdaq:ACER
- Legal Name
- Acer Therapeutics Inc.
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | Post-IPO Equity | $1.50M | — | — | — | Detail |
| Mar 7, 2022 | Post-IPO Debt | $48.50M | 2 | — | — | Detail |
| Sep 19, 2017 | Post-IPO Equity | $15.70M | 1 |
TVM Capital Life Science
|
— | Detail |
| Sep 19, 2017 | IPO | — | — | — | — | Detail |
| May 6, 2016 | Post-IPO Equity | $8.14M | 1 |
TVM Capital Life Science
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
TVM Capital Life Science
|
Yes | Post-IPO Equity |
Marathon Asset Management
|
— | Post-IPO Debt |
SWK Holdings
|
— | Post-IPO Debt |
Employee Profiles
Acquisition
Acer Therapeutics has acquired 1 organizations. Their most recent acquisition was Opexa Therapeutics on Sep 19, 2017. They acquired Opexa Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Sep 19, 2017
Opexa Therapeutics
|
Biotechnology | merge | — | Detail |
